Soligenix SNGX
NASDAQ SNGX
$0.36 +0.01 (+3.32%)
As of: Oct 22, 2026 · 1:09 PM EDT

Soligenix (SNGX) Current Deferred Revenue (2022)

Updated

Soligenix (SNGX) recorded Current Deferred Revenue of $100,000 in Q3 2022, unchanged from the prior quarter.

Analysis

Soligenix (SNGX) Current Deferred Revenue (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,170.64 Bn 1,139.23 Bn 19.71 Bn
2 Johnson & Johnson 647.91 Bn 567.77 Bn 17.30 Bn
3 AbbVie 503.02 Bn 476.13 Bn 12.70 Bn
4 Merck 365.11 Bn 319.49 Bn 12.21 Bn
5 Novartis Ag 303.38 Bn 267.37 Bn 11.24 Bn
6 Astrazeneca 268.87 Bn 242.56 Bn 12.86 Bn
7 Amgen 242.01 Bn 197.41 Bn 7.24 Bn
8 Gilead Sciences 194.74 Bn 168.94 Bn 6.22 Bn
9 Pfizer 172.37 Bn 119.01 Bn 10.94 Bn
10 Soligenix 5.77 Mn -28.53 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 100,000.00
Jun 30, 2022 100,000.00
API Access

Soligenix Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=SNGX&period=max&api_key=YOUR_API_KEY